Archimedes

Archimedes' Specialty PBM program offers plan sponsors a proven strategy for effective and sustainable #specialtydrug management. Some traditional #PBMs will attempt to charge employers extortionate fees to carve out specialty in order to preserve their own profits. If your PBM is putting up false barriers like this to protect their own interests, maybe it's time for a change. Archimedes has helped many employers navigate this challenge to realize 30-50% reductions in specialty drug spend. #pharmacybenefits

https://lnkd.in/ggzhYJ58 The recent withdrawal of Oxbryta is another sobering illustration of the importance of using an evidence-based approach to specialty drug coverage. While Archimedes has excluded this drug since its fast-track approval, employers working with PBMs who were less diligent have incurred unnecessary costs while putting these vulnerable patients at risk. It's time for a different approach to managing specialty drugs. #specialtydrug #pbms

Ever feel like your PBM thinks you have unlimited funds to pay for specialty drugs? Specialty medications can cost hundreds of thousands – or even millions per patient per year. A single high-cost specialty drug case can have a crippling effect on an employer’s financials. It's time for a new approach to managing specialty drugs. #specialtydrug #pharmacybenefits #pbms

Establishing a higher standard of patient care is a core component of Archimedes’ specialty drug programs. Paul McCann, our Senior Director of Member Services, has played a critical role in achieving this vision. Having served in member services leadership roles in the industry for decades, Paul saw firsthand the inadequacy of traditional PBM service models in addressing the unique challenges faced by specialty patients. He used this experience to build Archimedes model the right way from the ground up – creating a high touch experience that ushers these patients with complex conditions throughout the process. "We take great pride in going the extra mile to take exceptional care of our specialty members. No two specialty patients are the same." Under Paul’s exceptional leadership, Archimedes’ member services team provides unparalleled service and support to our patients with the same empathy and care that we would provide to a family member.

Hot off the presses – we are thrilled to share that Archimedes clients are experiencing a NEGATIVE YOY trend in the first half of 2024. Driven by a commitment to BiosimilarsFirst and rigorous clinical management, Archimedes’ model is designed to eliminate unnecessary costs while ensuring patients receive the care they need. This sits in stark contrast from typical increases in spend seen in the PBM industry. If you aren’t seeing a decrease in #specialtydrug spend in 2024, you are leaving money on the table. #biosimilars #negativetrend

The Archimedes team enjoyed celebrating our second year in a row being named to the prestigious #Inc5000 list of fastest-growing private companies. We are beyond thankful for the opportunity to work with our exceptional clients and partners in setting the new standard for specialty drug management. #specialtydrugs #pbm

We are excited to share that Archimedes has been named to the #Inc5000 list of fastest-growing companies in America for the second year in a row. Archimedes was built on a foundation of alignment and value-based care to address the challenge of rising specialty drug costs. Since our inception, we have built rigorous clinical processes, created robust technology and assembled a remarkable team of individuals who are passionate about providing true clinical care at the lowest net cost for specialty patients. If you are interested in learning how to save 30-54% on specialty spend, we would love to connect with you. To explore the full list, go to: https://lnkd.in/g6Yn3rnH

In the realm of high-cost specialty medications, ensuring patients have the right dosing regimen is paramount. Incorrect dosages can lead to severe side effects or diminished therapeutic effects, compromising patient health. Because specialty medications often come with a hefty price tag, incorrect dosing can also lead to wasted medication and increased healthcare costs. By ensuring the right dose, we can help manage these costs more effectively, making treatments more accessible to those in need. The attached patient case study offers a great example of the importance of rigorous management and monitoring of medication dosing. As a result of the Archimedes' clinical team's work, the patient received the care they needed while removing unnecessary costs for the plan. #specialtydrugs #pharmacybenefits

Is your plan throwing away money on unnecessary specialty drug spend? Skyrocketing specialty drug costs do not always provide good value - clinical benefit for the money spent. Research evidence indicates that many specialty drug claims are more costly than necessary, meaning that the price paid was too high for the clinical circumstance, and/or clinically inappropriate, meaning that the drug was used in a patient for whom it is likely to be ineffective or even harmful. Managing specialty requires a different approach. Our PA criteria are designed to reduce unnecessary, wasteful, and harmful uses of specialty medications. #specialtydrug #pharmacybenefits

This article provides a great illustration of what you can expect when #PBMs derive profits from every script - you simply cannot rely on their ability to act in the best interest of clients or patients. Built on a business model that is free from these conflicts, Archimedes is proud to offer Mark Cuban Cost Plus Drug Company, PBC and other low-cost pharmacies as part of our value-based pharmacy network. https://lnkd.in/g83cesKr